CME Presentations
Decoding GLP-1 Receptor Agonists and Simplifying Diabetes Care: An Individualized Educational Journey for Interprofessional Clinicians and Their Patients
Presentations
Module 1: Guidelines and Their Rationale: A 2021 Refresher
Speakers: Jay Shubrook, DO, FACOFP, FAAFP, Professor, Primary Care DepartmentDiana Isaacs, PharmD, BCPS, BCACP, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist Duration: 45 minutes
Presented on: August 16, 2021
Module 2: GLP-1 and Glucose Regulation
Speakers: Jay Shubrook, DO, FACOFP, FAAFP, Professor, Primary Care DepartmentDiana Isaacs, PharmD, BCPS, BCACP, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist Duration: 15 minutes
Presented on: August 16, 2021
Module 3: Magnifying Glass on the CV Properties of GLP-1 RAs
Speakers: Jay Shubrook, DO, FACOFP, FAAFP, Professor, Primary Care DepartmentDiana Isaacs, PharmD, BCPS, BCACP, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist Duration: 30 minutes
Presented on: August 16, 2021
Module 4: Magnifying Glass on the Renal Impacts of GLP-1 RA: Current and Future
Speakers: Jay Shubrook, DO, FACOFP, FAAFP, Professor, Primary Care DepartmentDiana Isaacs, PharmD, BCPS, BCACP, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist Duration: 30 minutes
Presented on: August 16, 2021
Module 5: Putting it All Together for GLP-1 Targeted Agents: One Size Does Not Fit All
Speakers: Jay Shubrook, DO, FACOFP, FAAFP, Professor, Primary Care DepartmentDiana Isaacs, PharmD, BCPS, BCACP, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist Duration: 30 minutes
Presented on: August 30, 2021
Module 6: Diabetes and Underserved Populations: Emergency Calling for Immediate Action
Duration: 30 minutes
Presented on: August 30, 2021
Speakers
Jay Shubrook, DO, FACOFP, FAAFP
Jay Shubrook, DO, FACOFP, FAAFP
Professor, Primary Care Department
Jay H. Shubrook, DO, FACOFP, FAAFP, is a board-certified family physician and a fellowship trained diabetologist in Vallejo, California. He is a professor in the Primary Care Department at Touro University California and serves both as the director of Clinical Research and director of Diabetes Services. Dr Shubrook’s passion is to better prepare the primary care workforce on the management of diabetes. His research explores early interventions in prediabetes and type 2 diabetes. Dr Shubrook is an associate editor of Clinical Diabetes.Session Appearances
Module 6: Diabetes and Underserved Populations: Emergency Calling for Immediate Action
Module 5: Putting it All Together for GLP-1 Targeted Agents: One Size Does Not Fit All
Module 3: Magnifying Glass on the CV Properties of GLP-1 RAs
Module 4: Magnifying Glass on the Renal Impacts of GLP-1 RA: Current and Future
Diana Isaacs, PharmD, BCPS, BCACP, CDCES, FADCES, FCCP
Diana Isaacs, PharmD, BCPS, BCACP, CDCES, FADCES, FCCP
Endocrine Clinical Pharmacy Specialist
Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, is the remote monitoring and continuous glucose monitoring (CGM) program coordinator and endocrinology clinical pharmacy specialist at the Cleveland Clinic Diabetes Center in Ohio. She presents on diabetes-related topics nationally and internationally. Dr Isaacs is communications director for the American Diabetes Association (ADA) Pregnancy and Reproductive Health Interest Group and serves on the 2020-2021 ADA Professional Practice Committee, which updates the ADA Standards of Care. She is also president of the Ohio Association of Diabetes Care and Education Specialists (ADCES). Dr Isaacs was awarded the Ohio Pharmacists Association Under 40 Award in 2019 and ADCES Diabetes Care and Education Specialist of the Year in 2020.Session Appearances
Module 6: Diabetes and Underserved Populations: Emergency Calling for Immediate Action
Technology and Telemedicine: Perspectives for Diabetes Care
Module 5: Putting it All Together for GLP-1 Targeted Agents: One Size Does Not Fit All
Module 3: Magnifying Glass on the CV Properties of GLP-1 RAs
Module 4: Magnifying Glass on the Renal Impacts of GLP-1 RA: Current and Future
Module 2: GLP-1 and Glucose Regulation
Nicolas Cuttriss, MD, MPH, FAAP
Nicolas Cuttriss, MD, MPH, FAAP
Founding Director
Nicolas Cuttriss, MD, MPH, FAAP, is a pediatric endocrinologist and social entrepreneur with a dedication to health disparities and improving the quality of life of people living with diabetes. He serves as founding director of Project ECHO Diabetes Action Network after serving as director of Project ECHO Diabetes and Project ECHO Diabetes in the Time of COVID-19 at Stanford University in California. Prior to joining Stanford, Dr Cuttriss served as the first pediatric endocrinologist for the Project ECHO Institute ENDO teleECHO clinic at University of New Mexico to democratize diabetes specialty knowledge by empowering primary care providers to care for patients with complex diabetes. He also founded ENDO Diabetes & Wellness, a medical practice specializing in diabetes and telehealth.
CME Information
Decoding GLP-1 Receptor Agonists and Simplifying Diabetes Care: An Individualized Educational Journey for Interprofessional Clinicians and Their Patients
LEARNING OBJECTIVES
After completing this activity, the participant should be better able to:- Individualize GLP-1 RA selection based on patient presentation and preference, including needs for glucose reduction, cardiovascular risk, weight, administration route, and frequency (Modules 1, 2, 3 & 5)
- Review data related to an improved understanding of the impact of GLP-1 RAs on kidney health and other microvascular outcomes (Modules 4 & 5)
- Implement the 2021 ADA standard of care pertaining to the use of GLP-1 RAs for reduction of hyperglycemia in people with T2DM (Modules 1 & 5)
- Enhance patient understanding of the rationale for selecting a GLP-1-receptor agonist as part of diabetes treatment and share strategies to manage adverse events Modules 1, 2, 3, 4 & 5)
- Describe strategies to enhance access to diabetes care among underserved, high-risk populations, such as African American patients and those in rural or disadvantaged areas (Module 6)
Jointly provided by Postgraduate Institute for Medicine (PIM) and PlatformQ Health Education, LLC (PQHE)
This activity is supported by an educational grant from Novo Nordisk, Inc.TUITION
Complimentary
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.LIVE CREDIT DESIGNATION STATEMENTS
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.0 contact hours.ENDURING CREDIT DESIGNATION STATEMENTS
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.0 contact hours.DATE OF RELEASE/EXPIRATION
Live Activity
Monday, August 30, 2021, from 10:00am – 11:00am ET- 10:00am – 10:30am ET: Putting it All Together for GLP-1 Targeted Agents: One Size Does Not Fit All
- 10:30 – 11:00am ET: Diabetes and Underserved Populations: Emergency Calling for Immediate Action
Enduring Material
The enduring material will be available from August 16, 2021 to August 30, 2022- Monday, August 16, 2021
- Guidelines and Their Rationale: A 2021 Refresher
- GLP-1 and Glucose Regulation
- Magnifying Glass on the CV Properties of GLP-1 RAs
- Magnifying Glass on the Renal Impacts of GLP-1 RA: Current and Future
- Monday, August 30, 2021
- Putting it All Together for GLP-1 Targeted Agents: One Size Does Not Fit All
- Diabetes and Underserved Populations: Emergency Calling for Immediate Action
TARGET AUDIENCE
This activity is intended for primary care providers, nurse practitioners, physician assistants, certified diabetes educators, nurses, pharmacists, and other care providers involved in the management of people with diabetes.ESTIMATED TIME TO COMPLETE
This activity consists of 6 modules which should take approximately 3 hours to complete.METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to www.DiabetesSeriesLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship Jay H. Shubrook, DO
Professor
Diabetologist
Touro University CaliforniaConsulting Fees: Astra Zeneca, Bayer, Novo Nordisk Diana Isaacs, PharmD, BCPS, BCACP, CDCES, FADCES, FCCP
Endocrine Clinical Pharmacy Specialist
CGM and Remote Monitoring Program Coordinator
Cleveland Clinic Diabetes CenterConsulting Fees: Speaker – Abbott, Dexcom, Insulet, Medtronic, Novo Nordisk; Advisory Board – Lilly Nicolas Cuttriss, MD, MPH, FAAP
Pediatric Endocrinologist
ENDO Diabetes & Wellness
Founding Director ECHO Diabetes Action NetworkConsulting Fees: The Leona M. and Harry B. Helmsley Charitable Trust; Cecelia Health
Other: Chairman of the Board, AYUDA
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship Carole Drexel
Medical Director
PlatformQ Health Education, LLCNone
The PIM planners and managers have nothing to disclose.
The following PlatformQ Health Education, LLC planners, Alissa Yost and Patricia Gellasch, PhD, APN-C, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support: Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.
Technical Support: For any technical issues or issues with your CME Certificate, please contact DiabetesSeriesLive at 877-394-1306 or at Support@DiabetesSeriesLive.com.
